Fibromyalgia Pipeline Assessment and Therapeutic Development with Drugs Presented in H2 2017

Posted on 2017-07-26 by Mark Hub in Pharmaceuticals // 0 Comments

Albany, US, 2017-Jul-26 — /EPR Network/ — Fibromyalgia is a widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues, that has no cure but medication can control the symptoms. So to minimize the symptom of the medical problem, the fibromyalgia drug needs to be analyzed and came up with the satisfying result through various therapeutic developments. To analyze the fibromyalgia pipeline overview, Market Research Hub (MRH) has recently added a research study which is titled as “Fibromyalgia – Pipeline Review, H2 2017” to its massive report database.

Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230570

Fibromyalgia (FM) is a medical condition characterized by chronic widespread pain and a heightened pain response to pressure, with other major symptom involving the tiredness that may affect normal work, sleep problems, and troubles with memory. The problem of the medical problem is unknown; however, it is estimated that it involves a combination of genetic and environmental factors with half the risk attributed to each. This condition runs in families and many genes are believed to be involved. It’s proper management cover, medication, behavioral intervention, and exercise.

The pipeline review starts with the fibromyalgia overview followed by the therapeutic development, assessment, and companies involved in therapeutic. The information on therapeutics under development for Fibromyalgia (Central Nervous System) is highlighted, with the analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews the key players involved in the pipeline therapeutic development along with the features dormant and discontinued projects.

Browse Full Report With TOC: http://www.marketresearchhub.com/report/fibromyalgia-pipeline-review-h2-2017-report.html

Companies involved in the therapeutic development are Astellas Pharma Inc., Daiichi Sankyo Company Ltd., Immune Therapeutics Inc., Innovative Med Concepts LLC, Intec Pharma ltd., Jiangsu Hengrui Medicine Co Ltd., KPI Therapeutics Inc., Merck & Co Inc., Pfizer Inc., Switch Biotech LLC. and Zynerba Pharmaceuticals Inc. Moreover the drugs under therapeutic development are also profiled that includes (cannabidiol + dronabinol), (celecoxib + famciclovir), AS-1069562, ASP-0819, ASP-8062, mirogabalin besylate, mirtazapine ODT, naltrexone hydrochloride, Peptide to Block Voltage-Dependent N-Type Calcium Channel for Central Nervous System, pregabalin CR, pregabalin SR, SWT-06101, U-2902, and ZYN-001. Thus concluding the detailed pipeline assessment of the fibromyalgia.

Ended by the featured news and press releases to give a trustful resource of the assessment. Additionally, this guide covers therapeutics under Development by Companies /Universities /Institutes. The therapeutic molecules developed by companies in the pipeline development under pre-registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5, 3 and 2 respectively. Additionally, the assessment also comprises various dynamic tracking processes that ensure that the most recent developments are captured on a real time basis.

Make An Enquiry: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1230570

About Market Research Hub:

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick